BDTX — Black Diamond Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1701541 ·
Last close
$1.75
Market Cap
$100.28M
52W High
$3.97
52W Low
$1.75
ADV30
1,859,050
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -11,259,000 | -9,036,000 | 132,922,000 | 30,071,000 | 28,622,000 |
| Dec 2025 | 0 | — | -10,262,000 | -15,116,000 | 143,010,000 | 20,990,000 | 30,799,000 |
| Sep 2025 | 0 | — | -10,978,000 | -8,498,000 | 157,733,000 | 30,864,000 | 31,581,000 |
| Jun 2025 | 0 | — | -13,420,000 | -10,561,000 | 166,385,000 | 29,993,000 | 33,775,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$29,614,000
Investing CF
$-44,905,000
Financing CF
$-146,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.37
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-464,740,000
Inventory
—
Receivables
—
ST Investments
$107,662,000
EBIT TTM
$19,870,000
Pretax Income TTM
$22,367,000
Interest Exp TTM
—
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-45,654,000
Free Cash Flow
$-25,891,376
Enterprise Value
$-97,895
Total Cash
$118,258,000
Total Debt
$17,882,000
Shares Out
57,301,774
Trailing EPS
$-0.77
Book Value
$1.82
ROE
-35.2%
ROA
-18.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 70,000,000 | 19,870,000 | 22,367,000 | 143,010,000 | 30,799,000 | — | 29,614,000 |
| Dec 2024 | 0 | -78,781,000 | -69,676,000 | 122,640,000 | 39,355,000 | — | -62,303,000 |
| Dec 2023 | 0 | -86,460,000 | -82,442,000 | 158,567,000 | 41,831,000 | — | -66,717,000 |
| Dec 2022 | 0 | -92,828,000 | -91,169,000 | 156,255,000 | 40,560,000 | — | -85,082,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-95,295,000
OpCashFlow TTM
$0
Assets (Latest)
$122,640,000
Forward EPS
$-1.16
Max Pain — expiry 2026-06-18
max pain strike: $2.50 · spot: $1.72 · call oi: 6,401 · put oi: 2,605
Expected Move to 2026-06-18:
±$1.23
(71.51%) —
implied range
$0.49 –
$2.95
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KLRS | Kalaris Therapeutics, Inc. | $103.02M | $4.33 | — |
| PTHS | Pelthos Therapeutics Inc. | $95.58M | $27.50 | — |
| CRDF | Cardiff Oncology, Inc. | $105.29M | $1.54 | — |
| ATRA | Atara Biotherapeutics, Inc. | $93.80M | $10.41 | — |
| CGTX | COGNITION THERAPEUTICS INC | $108.29M | $1.21 | — |
News headlines (Yahoo Finance, 1h cache)
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path
2026-06-06 09:04 · Yahoo
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
2026-05-27 15:16 · Yahoo
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
2026-05-27 15:13 · Yahoo
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
2026-05-27 15:10 · Yahoo
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
2026-05-25 14:53 · Yahoo
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
2026-05-22 12:00 · Yahoo
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study
2026-05-21 23:09 · Yahoo
Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
2026-05-21 21:13 · Yahoo
Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
2026-05-19 12:00 · Yahoo
BDTX Shares Gain 11% in a Week: Here's What You Should Know
2026-05-11 15:48 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.